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Abstract
Background: Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer,
both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients
have some neurotoxicity during treatment, the long-term outcome of chemotherapy-induced
neuropathy has been scantly studied. We retrospectively assessed the prevalence of residual
neuropathy in a cohort of patients in clinical remission after first-line carboplatin/paclitaxel for
advanced ovarian cancer.
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Methods: 120 patients have been included in this study (101 participating in a multicentre phase
III trial evaluating the efficacy of consolidation treatment with topotecan, and 19 treated at the
National Cancer Institute of Naples after the end of the trial). All patients received carboplatin
(AUC 5) plus paclitaxel (175 mg/m2) every 3 weeks for 6 cycles, completing treatment between
1998 and 2003. Data were collected between May and September 2004. Residual sensory and
motor neurotoxicity were coded according to the National Cancer Institute – Common Toxicity
Criteria.
Results:  55 patients (46%) did not experience any grade of neurological toxicity during
chemotherapy and of these none had signs of neuropathy during follow-up. The other 65 patients
(54%) had chemotherapy-induced neurotoxicity during treatment and follow-up data are available
for 60 of them. Fourteen out of 60 patients (23%) referred residual neuropathy at the most recent
follow-up visit, after a median follow up of 18 months (range, 7–58 months): 12 patients had grade
1 and 2 patients grade 2 peripheral sensory neuropathy; 3 patients also had grade 1 motor
neuropathy. The remaining 46/60 patients (77%) had no residual neuropathy at the moment of
interview: recovery from neurotoxicity had occurred in the first 2 months after the end of
chemotherapy in 22 (37%), between 2 and 6 months in 15 (25%), or after more than 6 months in
9 patients (15%). Considering all 120 treated patients, there was a 15% probability of persistent
neurological toxicity 6 months after the end of chemotherapy.
Conclusion: A significant proportion of patients with advanced ovarian cancer treated with first-
line carboplatin/paclitaxel suffer long-term residual neuropathy. This issue should be carefully taken
into account before considering re-treatment with the same agents in sensitive recurrent disease.
Background
The combination of carboplatin and paclitaxel is consid-
ered worldwide the standard first-line chemotherapy for
patients with advanced ovarian cancer [1-3]. This chemo-
therapy is highly effective, and about half of the patients
show a clinical complete remission after six cycles [1].
Unfortunately, most of these patients experience disease
recurrence. A significant proportion of recurring patients,
with a platinum-free interval longer than 6–12 months,
are classified as platinum-sensitive and are candidates for
re-treatment with the same drugs used in first-line [4].
However, the use of carboplatin and paclitaxel to treat
recurrent disease may be limited by the risk of cumulative
peripheral neurotoxicity, a common side effect of this
combination when given as first-line chemotherapy in
ovarian cancer. Grade 2–3 sensory toxicity, according to
the National Cancer Institute Common Toxicity Criteria
[5] is reported in about 25% of the patients, and also
motor toxicity can be experienced, although less fre-
quently [1-3,6,7]. The most common feature of carbopla-
tin/paclitaxel neurotoxicity is sensory distal neuropathy
[8]. A mixture of paresthesias and dysesthesias is often
prominent, and complaints include burning dysesthesia,
numbness, tingling and shooting, typically in a stocking-
glove distribution. The peripheral neuropathy related to
carboplatin/paclitaxel is due to axonopathy, while motor
and autonomic nerves appear to be less affected. Mild
weakness is the most common complaint of motor toxic-
ity, generally due to distal motor neuropathy [8].
The occurrence of neurotoxicity may have significant
effects on quality of life, and several reliable instruments
containing items specifically addressing symptoms related
to neurotoxicity have been developed [9,10]. These instru-
ments have been used in randomized studies comparing
cisplatin/paclitaxel versus carboplatin/paclitaxel [1] and
docetaxel/carboplatin versus paclitaxel/carboplatin [7].
Despite the attention dedicated to neurotoxicity, the long-
term outcome of peripheral neuropathy induced by car-
boplatin/paclitaxel has not been deeply investigated. In
particular, the proportion of platinum-sensitive recurring
patients who are candidates for retreatment with the same
regimen, but who are at increased risk of cumulative tox-
icity because of residual neuropathy, has not been evalu-
ated.
In this study, we retrospectively evaluated the prevalence
of residual neuropathy in a cohort of ovarian cancer
patients in clinical remission following first-line chemo-
therapy with carboplatin and paclitaxel.
Methods
Patients included in this analysis received first-line chem-
otherapy for advanced ovarian cancer between 1998 and
2003. Most of the patients participated in the Multicenter
Italian Trials in Ovarian cancer (MITO)-1 study [11], that
was a randomized phase III trial that evaluated the efficacy
of consolidation treatment with topotecan in patients
responding to first-line chemotherapy with carboplatinBMC Cancer 2006, 6:5 http://www.biomedcentral.com/1471-2407/6/5
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and paclitaxel. At the moment of the present retrospective
study (May–September 2004), 101 out of the 273 patients
enrolled in the MITO-1 study were in clinical remission
and were eligible for the present analysis. Among these
patients, 41 had received 4 cycles of topotecan, at the dose
of 1.5 mg/sm from day 1 to 5 every 3 weeks, after comple-
tion of the 6 cycles of carboplatin and paclitaxel, accord-
ing to the MITO-1 protocol; these patients were not
excluded from this analysis because topotecan is not
expected to produce significant neurotoxicity. A further
group of 19 patients, among those treated at the National
Cancer Institute of Naples after the end of the MITO-1
accrual, were in clinical remission at the moment of this
study and were eligible for this retrospective study. For all
of the 120 patients described above, primary treatment
was carboplatin – area under the curve (AUC) 5 – and
paclitaxel – 175 mg/sm given in a 3-hour infusion.
This was designed as a retrospective study, so specific
approval by the Ethics Committee was not required by the
Italian law. Of course, all the patients participating in the
MITO-1 trial gave a written informed consent before any
study procedure. The other 19 patients received first-line
treatment with carboplatin and paclitaxel as part of the
standard clinical practice at the National Cancer Institute
of Naples.
Information about neurotoxicity experienced by the
patients during the treatment was collected from the data-
base of the MITO-1 trial for 101 patients, and from clini-
cal files for the remaining 19 patients treated outside the
trial. Residual neurotoxicity was evaluated by the physi-
cian and graded according to the NCI-CTC criteria, ver-
sion 2.0 [5]. According to these criteria, sensory
neuropathy is coded as grade 1 (loss of deep tendon
reflexes or paresthesia, including tingling, but not interfer-
ing with function), grade 2 (objective sensory loss or par-
esthesia, including tingling, interfering with function, but
not interfering with activities of daily living), grade 3 (sen-
sory loss or paresthesia interfering with activities of daily
living) or grade 4 (permanent sensory loss that interferes
with function). Motor neuropathy is coded as grade 1
(subjective weakness but no objective findings), grade 2
(mild objective weakness interfering with function, but
not interfering with activities of daily living), grade 3
(objective weakness interfering with activities of daily liv-
ing) or grade 4 (paralysis).
Follow-up data were collected between May and Septem-
ber 2004. After performing a clinical examination and an
interview, the participating investigators completed a ded-
icated case report form for each patient, reporting the
grade of any residual sensory and/or motor neurotoxicity.
Details of pharmacological treatments administered for
neuropathy were also collected. For those patients who
had experienced neurotoxicity during chemotherapy but
had no residual neuropathy at the moment of the inter-
view, the investigator reported the date of resolution of
neuropathy, as referred by the patient.
Time to resolution of neuro-toxicity was defined as the
interval from the end of chemotherapy with carboplatin
Table 1: Characteristics of neurological toxicity during or after first-line chemotherapy with carboplatin plus paclitaxel
Neurological toxicity No. of patients %
A. during chemotherapy (n = 120)
No toxicity 55 (46%)
At least grade 1 toxicity 65 (54%)
Type of toxicity
Sensory, grade 1 51 (42%)
Sensory, grade 2 13 (11%)
Sensory, grade 3 1 (1%)
Motor, grade 1 (combined with sensory) 3 (3%)
B. residual toxicity after chemotherapy (n = 60 - 5 patients lost)
No toxicity at the moment of interview 46 (77%)
Time to recovery from residual neuropathy
< 2 months after the end of chemotherapy 22 37%
≥ 2 < 6 months after the end of chemotherapy 15 25%
≥ 6 months after the end of chemotherapy 9 15%
At least grade 1 residual toxicity at the moment of 
interview
14 (23%)
Type of residual toxicity
Sensory, grade 1 12 (20%)
Sensory, grade 2 2 (3%)
Motor, grade 1 (combined with sensory) 3 (5%)BMC Cancer 2006, 6:5 http://www.biomedcentral.com/1471-2407/6/5
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and paclitaxel to the date of resolution of neuro-toxicity or
the date of last follow-up information for patients with
residual neuro-toxicity. Time to resolution curve was
drawn with the Kaplan-Meier product limit method [12].
Analyses were performed with S-PLUS software (S-PLUS
6.0 Professional, release 1; Insightful Corporation, Seattle,
WA, USA).
Results
The median age of the 120 patients included in the study
was 56 years (range, 26–72). The median follow-up,
defined as the interval between the end of chemotherapy
and the date of the interview, was 48 months (range 7–
74).
Table 1 shows the details of neurotoxicity recorded during
treatment with carboplatin and paclitaxel, and the details
of residual neuropathy. Fifty-five patients (46%) did not
suffer neurological toxicity during chemotherapy, and
none of these patients had signs of neuropathy at the
moment of the interview. The remaining 65 patients
(54%) suffered neurological toxicity during chemother-
apy. In particular, 51 patients (42%) experienced grade 1
sensory neuropathy, 13 (11%) grade 2 sensory neuropa-
thy and 1 (1%) grade 3 sensory neuropathy. Three
patients experienced motor deficit in addition to sensory
neuropathy.
Follow-up data are available for 60 out of the 65 patients
who experienced neurotoxicity during chemotherapy.
Forty-six patients (77%) reported resolution of neuropa-
thy during follow-up and had no residual neuropathy at
the moment of interview. Complete recovery occurred in
the first 2 months after the end of chemotherapy in 22
patients (37%), but 15 patients (25%) recovered from
neuropathy between 2 and 6 months, and 9 patients
(15%) after 6 months or more. The remaining 14 out of
60 cases (23%) had some grade of residual neuropathy at
the moment of assessment (median follow-up 23
months, range 7–58). Most of these patients suffered from
grade 1 peripheral sensory neuropathy (12 patients), but
2 patients had grade 2 sensory neuropathy and 3 patients
reported complaints derived by a grade 1 motor neuropa-
thy in addition to sensory neurotoxicity. Considering all
120 patients who received combination chemotherapy
with carboplatin and paclitaxel, the probability of neuro-
logical toxicity for a patient was 54% during chemother-
apy, 15% at 6 months after the end of chemotherapy, 14%
at 1 year after the end of chemotherapy and 11% at 2 years
after the end of chemotherapy (Figure 1). No significant
difference (p = 0.94) was found in the duration of neuro-
logical toxicity when patients were divided in two cohorts
according to age, younger or older than 60 (Figure 2).
Figure 3 shows the time to resolution of neurotoxicity
according to its severity. Six-months probability of resid-
ual neuropathy was 27.1% for patients suffering from
grade 1 neurotoxicity at the end of chemotherapy and
33.3% for patients with grade 2 or more. 1-year probabil-
ity of residual neuropathy was 23.7% and 33.3%, and 2-
year probability was 19.7% and 22.2%, for patients with
grade 1 and grade 2 or more, respectively. Difference of
time to resolution among the two groups of patients was
not statistically significant (p = 0.716, Log-rank test).
No specific pharmacological therapy for neurotoxicity
was delivered, with the exception of one patient who
received corticosteroids and gabapentin.
Discussion
In the present retrospective analysis, we explored the prev-
alence of residual neuropathy in a cohort of patients with
advanced ovarian cancer in complete remission after first-
line chemotherapy. Our data show that a significant pro-
portion of patients who experience neurological toxicity
during treatment with carboplatin and paclitaxel suffer
from prolonged residual neuropathy during their progres-
sion-free follow-up.
Three randomized studies have compared carboplatin/
paclitaxel versus cisplatin/paclitaxel as first-line chemo-
therapy in advanced ovarian cancer [1-3]. All these studies
showed that carboplatin/paclitaxel induces lower neuro-
toxicity, with a significant positive impact on quality of
life. Based on these results, the combination of carbopla-
tin and paclitaxel is now considered the chemotherapy of
Kaplan-Meyer curve of time to resolution of neurological  toxicity in patients with epithelial ovarian carcinoma treated  with the combination of carboplatin and paclitaxel (dotted  lines represent 95% confidence interval) Figure 1
Kaplan-Meyer curve of time to resolution of neurological 
toxicity in patients with epithelial ovarian carcinoma treated 
with the combination of carboplatin and paclitaxel (dotted 
lines represent 95% confidence interval).
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choice for ovarian cancer. Nevertheless, about 40% of
patients treated with carboplatin and paclitaxel experi-
ence grade 1, 21% grade 2 and 6% grade 3 neurotoxicity
during treatment [1-3]. The presence of residual neuropa-
thy is an even more important issue after the publication
of the ICON-4 study, that showed a survival benefit for
platinum-sensitive recurrent patients treated with carbo-
platin/paclitaxel combination, compared to carboplatin
alone [4]. The persistence of residual neuropathy could
increase the risk of cumulative toxicity, and limit the use
of carboplatin/paclitaxel in the recurrence setting. Fur-
thermore, the debated maintenance strategy, with
extended administration of paclitaxel after complete
response to first-line chemotherapy, supported by the
study of Markman et al. [13], can be seriously limited by
the persistence of residual neuropathy.
In our analysis after a median follow-up of 48 months,
while none of the patients without neurotoxicity during
first-line had signs of neuropathy during follow-up, 23%
of patients with chemotherapy-induced neurological tox-
icity had residual neuropathy. Neuropathy was in most
cases sensory, but three cases also had residual weakness
related to motor damage. Furthermore, within the group
of patients without residual neuropathy at the time of
study assessment, a significant proportion had recovery
from neuropathy more than 6 months after the end of
treatment. It should be noted that probability of long-
term persistence of neurotoxicity was not negligible either
for patients experiencing moderate to severe toxicity dur-
ing chemotherapy, or those patients suffering from grade
1 toxicity.
These data suggest that residual neuropathy could affect a
proportion of patients higher than believed. Since the
patients that experience recurrent disease after more than
6 months from the end of chemotherapy are candidates
for re-treatment with carboplatin/paclitaxel [4], it seems
important to recommend an accurate assessment of the
presence of residual neuropathy before starting re-treat-
ment. Recent data show that treatment with paclitaxel
may induce cumulative neurotoxicity in patients with
neuropathy during a previous cisplatin-based chemother-
apy [14]. The results of the ICON-4 study show that re-
treatment with carboplatin and paclitaxel is associated
with neurotoxicity grade 2–3 in up to 20% of the patients
[4].
Unfortunately, the retrospective nature of our study did
not allow an evaluation of the effects of neuropathy on
health-related quality of life. This may be an important
issue particularly for early stage ovarian cancer patients
treated with carboplatin/paclitaxel adjuvant therapy. In
the phase III randomized trial performed by the Scottish
Gynaecological Cancer Trials Group, comparing the com-
bination of carboplatin and docetaxel with the standard
carboplatin/paclitaxel combination, health-related qual-
ity of life was one of the secondary end-points of the study
[7]. Coherently with the higher incidence of neurotoxicity
in the carboplatin/paclitaxel arm, quality of life scores
related to neurotoxicity deteriorated more in this arm, and
patients treated with carboplatin/paclitaxel reported sig-
nificantly worse scores for acute, persistent and long-term
(6-months after treatment) neurotoxicity. These data,
together with our results, emphasize that the risk of resid-
ual long-term neuropathy should be weighted with the
potential benefit of adding paclitaxel to carboplatin in the
re-treatment of these patients.
In our opinion, research in the field of prevention of neu-
rological toxicity is mandatory. Some pharmacological
attempts have been done with chemoprotective agents,
administered with the aim of minimizing chemotherapy-
induced neurotoxicity. Conflicting data have been pub-
lished on the effect of amifostine in preventing carbopla-
tin/paclitaxel neurotoxicity. Although "in vitro" data
indicate that amifostine can prevent neurotoxicity [15],
clinical data are not so clear [16,17]. Some findings sug-
gest that acetyl-L-carnitine can have a protective role
against paclitaxel/cisplatin neurotoxicity [18]. However,
as confirmed by the finding that only one patient in our
study received a pharmacological treatment for neurotox-
icity, none of these drugs are used in clinical practice.
Conclusion
Our data indicate that a significant proportion of patients
treated with first-line chemotherapy with carboplatin and
paclitaxel have long-term residual neuropathy. This issue
Duration of residual neuro-toxicity according to age cate- gory Figure 2
Duration of residual neuro-toxicity according to age cate-
gory.
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should be carefully taken into account before considering
a re-treatment with carboplatin and paclitaxel in sensitive
recurrent disease.
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